Palisade Bio reports Phase 1B Crohn's data at UEGW showing 47.5% reduction in endoscopic disease activity

Palisade Bio announced findings presented at United European Gastroenterology Week: a five-patient Phase 1B Crohn's disease cohort showed a 47.5% reduction in mean endoscopic disease activity and a 58.8% reduction in mean fecal calprotectin after 14 days. The Phase 2b ASCENTRA-UC study is enrolling and a Phase 2a Crohn's disease study is being initiated.

Detected & updated continuously · Source: Nebula